Praxis Precision Medicines
PRAX
69 hedge funds and large institutions have $1.96B invested in Praxis Precision Medicines in 2020 Q4 according to their latest regulatory filings, with 69 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
6.31% more ownership
Funds ownership: 0% → 6.31% (+6.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
+$331M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$140M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$137M |
| 4 |
VVA
Vida Ventures Advisors
Boston,
Massachusetts
|
+$114M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$95M |
Top Sellers
PRAX Hedge Fund Activity: Q4 2020 in Review
69 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q4 2020, worth a combined $1.96B.
Buyers outnumbered sellers: 69 funds opened new PRAX positions and 0 closed out — a net gain of 69 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Blackstone Inc, opening a new position worth an estimated $331M.
- 69 institutional investors held Praxis Precision Medicines (PRAX) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $1.96B of Praxis Precision Medicines stock for Q4 2020.
- 69 funds opened new Praxis Precision Medicines positions in Q4 2020 and 0 closed out, a net change of +69 holders.
- The largest Praxis Precision Medicines buyer in Q4 2020 was Blackstone Inc, an estimated $331M added.
Based on aggregated 13F filings for Q4 2020.